Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868569 | 1.00 | NAMPT (0.61) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL633936 | 1.00 | NAMPT (0.61) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL364174 | 0.90 | NPC1 (0.62) | NAMPTNPC1RAB9AMEN1KMT2A | |
| Water SCHEMBL30838095 | 0.88 | NPC1 (0.60) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12505662 | 0.86 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14797411 | 0.84 | NAMPT (0.52) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL27962735 | 0.83 | KDM1A (0.54) | NAMPTNPC1RAB9AKDM1AHPGDS | |
| SCHEMBL30968148 | 0.83 | ALDH1A1 (0.52) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL30968047 | 0.83 | ALDH1A1 (0.52) | NAMPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL23387883 | 0.82 | ALDH1A1 (0.59) | NAMPTRAB9ASMN1; SMN2HPGDSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117647598-A | High performance liquid analysis method for enantiomer of (S) -3-amino tetrahydrofuran and intermediate | 上海司太立制药有限公司 | 2024-03-05 | — | — | CN | claimed |
| US-20240400564-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-117956992-A | MENIN-MLL interaction inhibitors | 赛达克斯制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4337203-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Syndax Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117647598-A | High performance liquid analysis method for enantiomer of (S) -3-amino tetrahydrofuran and intermediate | 上海司太立制药有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11919901-B2 | Inhibitors of the menin-MLL interaction | SYNDAX PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230021684-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022241265-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | SYNDAX PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919901-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | NAMPT 1760/4885NPC1 2910/4885RAB9A 1287/4885 |
| US-20240400564-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | NAMPT 1744/4885NPC1 2965/4885RAB9A 1297/4885 |
| US-20230021684-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | NAMPT 1744/4885NPC1 2965/4885RAB9A 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.